Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

44 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pulmonary hypertension in idiopathic pulmonary fibrosis with mild-to-moderate restriction.
Raghu G, Nathan SD, Behr J, Brown KK, Egan JJ, Kawut SM, Flaherty KR, Martinez FJ, Wells AU, Shao L, Zhou H, Henig N, Szwarcberg J, Gillies H, Montgomery AB, O'Riordan TG. Raghu G, et al. Among authors: szwarcberg j. Eur Respir J. 2015 Nov;46(5):1370-7. doi: 10.1183/13993003.01537-2014. Epub 2015 Aug 6. Eur Respir J. 2015. PMID: 26250495 Free article. Clinical Trial.
Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.
du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, Lancaster L, Noble PW, Raghu G, Sahn SA, Szwarcberg J, Thomeer M, Valeyre D, King TE Jr. du Bois RM, et al. Among authors: szwarcberg j. Am J Respir Crit Care Med. 2011 Aug 15;184(4):459-66. doi: 10.1164/rccm.201011-1790OC. Am J Respir Crit Care Med. 2011. PMID: 21616999 Free article.
Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.
du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, Lancaster L, Noble PW, Sahn SA, Szwarcberg J, Thomeer M, Valeyre D, King TE Jr. du Bois RM, et al. Among authors: szwarcberg j. Am J Respir Crit Care Med. 2011 May 1;183(9):1231-7. doi: 10.1164/rccm.201007-1179OC. Epub 2010 Dec 3. Am J Respir Crit Care Med. 2011. PMID: 21131468 Free article. Clinical Trial.
Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.
King TE Jr, Albera C, Bradford WZ, Costabel U, Hormel P, Lancaster L, Noble PW, Sahn SA, Szwarcberg J, Thomeer M, Valeyre D, du Bois RM; INSPIRE Study Group. King TE Jr, et al. Among authors: szwarcberg j. Lancet. 2009 Jul 18;374(9685):222-8. doi: 10.1016/S0140-6736(09)60551-1. Epub 2009 Jun 29. Lancet. 2009. PMID: 19570573 Clinical Trial.
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.
Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, King TE Jr, Lancaster L, Sahn SA, Szwarcberg J, Valeyre D, du Bois RM; CAPACITY Study Group. Noble PW, et al. Among authors: szwarcberg j. Lancet. 2011 May 21;377(9779):1760-9. doi: 10.1016/S0140-6736(11)60405-4. Epub 2011 May 13. Lancet. 2011. PMID: 21571362 Clinical Trial.
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks.
Sax PE, DeJesus E, Mills A, Zolopa A, Cohen C, Wohl D, Gallant JE, Liu HC, Zhong L, Yale K, White K, Kearney BP, Szwarcberg J, Quirk E, Cheng AK; GS-US-236-0102 study team. Sax PE, et al. Among authors: szwarcberg j. Lancet. 2012 Jun 30;379(9835):2439-2448. doi: 10.1016/S0140-6736(12)60917-9. Lancet. 2012. PMID: 22748591 Clinical Trial.
44 results